Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Geron (Nasdaq: GERN) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 11:00 a.m. ET. A live audio webcast and archived audio will be available via the Investors & Media section at geron.com.
Positive
- None.
Negative
- None.
News Market Reaction – GERN
In the Apr 6 session, GERN gained 5.42%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.4% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Board appointments | Positive | -1.9% | Added two experienced biopharma leaders to support RYTELO commercial strategy. |
| Mar 18 | Inducement grants | Neutral | +0.0% | Granted 956,250 stock options to six new hires under inducement plan. |
| Feb 25 | Earnings & outlook | Positive | -11.8% | Reported strong RYTELO revenue, cash of $401.1M, and reiterated 2026 guidance. |
| Feb 23 | Investor conferences | Neutral | -5.8% | Announced March investor conference appearances with webcast access for investors. |
| Feb 18 | Inducement grant | Neutral | -1.0% | Issued 742,500 stock options to a new hire with 10-year term and vesting schedule. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including positive operational and financial updates, has often been followed by negative price reactions.
Over the last several months, Geron has reported growing RYTELO commercialization, including Q4 2025 revenue and 2026 guidance, alongside ample cash and a Pharmakon loan facility amendment (Jan 2026). However, earnings on Feb 25, 2026 saw a -11.79% move despite seemingly constructive metrics. Board refreshment and inducement grants in February–March had muted-to-negative reactions. Participation in another investor conference fits an ongoing pattern of active investor outreach without historically strong price support.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:00 a.m. ET.
A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
